Scientific American’s take on reducing readmissions through cutting-edge technology

One in five Medicare patients return to the hospital within a month after discharge, so it isn’t surprising that the federal government is pushing forward an agenda to discourage costly readmissions. Come October, hospitals with chronic readmission problems with patients struggling with heart failure, pneumonia and heart attack will face Medicare reimbursement penalties.

With this federal pressure on the horizon, an April 9 Scientific American article delves into all the promising technology—such as telehealth and mobile devices, microchipped medications and accessible digital health records—that could keep patients and physicians connected post discharge and bring down expensive readmissions in the process.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.